Cargando…
Approach to the Patient: “Utility of the Copeptin Assay”
Copeptin derives from the same precursor peptide preprovasopressin as arginine vasopressin (AVP). The secretion of both peptides is stimulated by similar physiological processes, such as osmotic stimulation, hypovolemia, or stress. AVP is difficult to measure due to complex preanalytical requirement...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113794/ https://www.ncbi.nlm.nih.gov/pubmed/35137148 http://dx.doi.org/10.1210/clinem/dgac070 |
_version_ | 1784709646518321152 |
---|---|
author | Christ-Crain, Mirjam Refardt, Julie Winzeler, Bettina |
author_facet | Christ-Crain, Mirjam Refardt, Julie Winzeler, Bettina |
author_sort | Christ-Crain, Mirjam |
collection | PubMed |
description | Copeptin derives from the same precursor peptide preprovasopressin as arginine vasopressin (AVP). The secretion of both peptides is stimulated by similar physiological processes, such as osmotic stimulation, hypovolemia, or stress. AVP is difficult to measure due to complex preanalytical requirements and due to technical difficulties. In the last years, copeptin was found to be a stable, sensitive, and simple to measure surrogate marker of AVP release. Different immunoassays exist to measure copeptin. The 2 assays which have most often be used in clinical studies are the original sandwich immunoluminometric assay and its automated immunofluorescent successor. In addition, various enzyme-linked immunosorbent assay have been developed. With the availability of the copeptin assay, the differential diagnosis of diabetes insipidus was recently revisited. The goal for this article is therefore to first review the physiology of copeptin, and second to describe its use as marker for the differential diagnosis of vasopressin-dependent fluid disorders, mainly diabetes insipidus but also hyper- and hyponatremia. Furthermore, we highlight the role of copeptin as prognostic marker in other acute and chronic diseases. |
format | Online Article Text |
id | pubmed-9113794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91137942022-05-18 Approach to the Patient: “Utility of the Copeptin Assay” Christ-Crain, Mirjam Refardt, Julie Winzeler, Bettina J Clin Endocrinol Metab Approach to the Patient Copeptin derives from the same precursor peptide preprovasopressin as arginine vasopressin (AVP). The secretion of both peptides is stimulated by similar physiological processes, such as osmotic stimulation, hypovolemia, or stress. AVP is difficult to measure due to complex preanalytical requirements and due to technical difficulties. In the last years, copeptin was found to be a stable, sensitive, and simple to measure surrogate marker of AVP release. Different immunoassays exist to measure copeptin. The 2 assays which have most often be used in clinical studies are the original sandwich immunoluminometric assay and its automated immunofluorescent successor. In addition, various enzyme-linked immunosorbent assay have been developed. With the availability of the copeptin assay, the differential diagnosis of diabetes insipidus was recently revisited. The goal for this article is therefore to first review the physiology of copeptin, and second to describe its use as marker for the differential diagnosis of vasopressin-dependent fluid disorders, mainly diabetes insipidus but also hyper- and hyponatremia. Furthermore, we highlight the role of copeptin as prognostic marker in other acute and chronic diseases. Oxford University Press 2022-02-08 /pmc/articles/PMC9113794/ /pubmed/35137148 http://dx.doi.org/10.1210/clinem/dgac070 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Approach to the Patient Christ-Crain, Mirjam Refardt, Julie Winzeler, Bettina Approach to the Patient: “Utility of the Copeptin Assay” |
title | Approach to the Patient: “Utility of the Copeptin Assay” |
title_full | Approach to the Patient: “Utility of the Copeptin Assay” |
title_fullStr | Approach to the Patient: “Utility of the Copeptin Assay” |
title_full_unstemmed | Approach to the Patient: “Utility of the Copeptin Assay” |
title_short | Approach to the Patient: “Utility of the Copeptin Assay” |
title_sort | approach to the patient: “utility of the copeptin assay” |
topic | Approach to the Patient |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113794/ https://www.ncbi.nlm.nih.gov/pubmed/35137148 http://dx.doi.org/10.1210/clinem/dgac070 |
work_keys_str_mv | AT christcrainmirjam approachtothepatientutilityofthecopeptinassay AT refardtjulie approachtothepatientutilityofthecopeptinassay AT winzelerbettina approachtothepatientutilityofthecopeptinassay |